Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma.
- Author:
Do Seon SONG
1
;
Si Hyun BAE
Author Information
- Publication Type:Review
- Keywords: Hepatocellular carcinoma; Sorafenib; Hepatic arterial infusion chemotherapy; Radioembolization
- MeSH: Carcinoma, Hepatocellular*; Drug Therapy; Humans; Liver Neoplasms; Survival Rate
- From:Journal of Liver Cancer 2016;16(1):1-6
- CountryRepublic of Korea
- Language:English
- Abstract: Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed.
